提升的TyG-BMI显著增加了急性缺血性中风和高血压患者1年的中风复发风险
Yan Liu1,2, Zhongzhong Liu1,2,3, Qingli Lu1,2
1Department of Neurology, Xi'an No. 1 Hospital, The First Affiliated Hospital of Northwest University, Xi'an, China.
Frontiers in endocrinology
|November 7, 2025
概括
增加的甘油三-葡萄糖-体重指数 (TyG-BMI) 与急性缺血性中风 (AIS) 和高血压患者中风复发风险增加有关. 这种关联在女性中是显著的,特别是那些TyG-BMI低于221.97.9的女性.
科学领域:
- 心脏病学 心脏病学
- 神经学 神经学
- 代谢综合征是代谢综合征的一种.
背景情况:
- 高血压和急性缺血性中风 (AIS) 是全球重要的健康问题.
- 三甘油-葡萄糖-体重指数 (TyG-BMI) 正在成为代谢功能障碍的标志物.
- 了解中风复发的风险因素对于患者管理至关重要.
研究的目的:
- 调查TyG-BMI与AIS和高血压患者中风复发1年风险之间的关联.
- 探索这种关联中的潜在的性别特异性差异.
主要方法:
- 一项追溯的多中心队列研究,涉及1,620名患有AIS和高血压的患者.
- 用多变量Cox比例危险模型和子组分析来评估这种关联.
- 进行了性别特定的分层分析,以确定效果的修改.
主要成果:
- 提升的TyG-BMI与更高的1年中风复发风险 (HR=1.06) 有显著的关联.
- 这种关联在女性中更为明显 (HR=1.18),Q3和Q4 TyG-BMI组的风险明显高于Q1.
- 观察到一个显著的性别特定的非线性关系;对于TyG-BMI低于221.97的女性,风险随着每个单位的增加而增加.
结论:
- 提升的TyG-BMI是高血压AIS患者中1年中风复发的独立预测因素.
- 这种关联是显著的,在女性中更为明显,特别是在TyG-BMI值221.97.7以下.
- 在特定患者群体中,TyG-BMI可能作为分层分层中风复发风险的有价值生物标志物.
相关概念视频
Hypertension II: Pathophysiology
765
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
765
Hypertension I: Introduction
721
Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
721
Hypertension III: Clinical Manifestations and Diagnostic Studies
452
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
452
Hypertension IV: Drug Therapy and Lifestyle Modifications
600
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
600
Hypertension and Regulation of Blood Pressure
3.6K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
3.6K
Atherosclerosis III: Management
307
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
307


